Anzeige
Mehr »
Login
Samstag, 08.08.2020 Börsentäglich über 12.000 News von 643 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PGJ3 ISIN: US0076243072 Ticker-Symbol: FAD2 
Tradegate
07.08.20
20:26 Uhr
0,478 Euro
-0,001
-0,10 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ADVAXIS INC Chart 1 Jahr
5-Tage-Chart
ADVAXIS INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,4640,47311:04
0,4610,47107.08.

Aktuelle News zur ADVAXIS Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoAdvaxis inks $20M stock purchase agreement with Lincoln Park Capital1
MoAdvaxis, Inc.: Advaxis Announces Common Stock Purchase Agreement for up to $20 Million with Lincoln Park Capital2
MoAdvaxis, Inc. - 8-K, Current Report3
ADVAXIS Aktie jetzt für 0€ handeln
11.06.Advaxis, Inc. (ADXS) CEO Ken Berlin on Q2 2020 Results - Earnings Call Transcript15
11.06.Advaxis, Inc. - 10-Q, Quaterly Report8
11.06.BRIEF-Advaxis Posts Quarterly Loss Per Share $0.1016
14.05.BRIEF-Advaxis Announces Updated Positive Clinical And Biomarker Data From Ongoing Phase 1/2 Adxs-503 Trial In NSCLC13
08.05.BRIEF-Advaxis - Entered Into Sales Agreement Pursuant To Which Co May Offer & Sell Up To Aggregate Of $40 Million Of Co's Shares19
20.04.Advaxis, Inc. - 8-K, Current Report11
10.04.BRIEF-Advaxis Says Received Notice That It Is Not In Compliance With Nasdaq Listing Rule13
10.04.Advaxis, Inc. - 8-K, Current Report5
16.03.Advaxis Is One Biotech That Should Be On Your Radar; Targeting Large NSCLC And Prostate Cancer Drug Markets26
13.03.Advaxis EPS beats by $0.0410
13.03.Advaxis, Inc.: Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update5
27.02.Advaxis, Inc. - 8-K, Current Report7
27.02.BRIEF-Advaxis Announces Updated Positive Clinical Data In Ongoing Phase 1/2 ADXS-503 Trial In NSCLC5
20.02.Advaxis, Inc. - 8-K, Current Report3
13.02.Advaxis' ADXS-PSA extends survival in prostate cancer patients14
13.02.ADXS, TROV On Watch, NRBO Soars 95%, DCPH To Face FDA In Aug.16
11.02.Advaxis teams up with Personalis for ADXS-503 program; shares up 13% premarket4
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1